SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Dahl Inger Marie)
 

Sökning: WFRF:(Dahl Inger Marie) > (2010-2014) > Effect of pamidrona...

  • Gimsing, PeterRigshosp, Copenhagen (författare)

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

  • Artikel/kapitelEngelska2010

Förlag, utgivningsår, omfång ...

  • Elsevier Science B.V., Amsterdam.2010
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-61183
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-61183URI
  • https://doi.org/10.1016/S1470-2045(10)70198-4DOI
  • https://lup.lub.lu.se/record/1720732URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-133595URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma. Methods This double-blind, randomised, phase 3 trial was undertaken at 37 clinics in Denmark, Norway, and Sweden. Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years. Randomisation was done by use of a central, computerised minimisation system. Primary outcome was physical function after 12 months estimated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire (scale 0-100). All patients who returned questionnaires at 12 months and were still on study treatment were included in the analysis of the primary endpoint. This study is registered with ClinicalTrials. gov, number NCT00376883. Findings From January, 2001, until August, 2005, 504 patients were randomly assigned to pamidronate 30 mg or 90 mg (252 in each group). 157 patients in the 90 mg group and 156 in the 30 mg group were included in the primary analysis. Mean physical function at 12 months was 66 points (95% CI 62.9-70.0) in the 90 mg group and 68 points (64.6-71.4) in the 30 mg group (95% CI of difference -6.6 to 3.3; p=0.52). Median time to first skeletal-related event in patients who had such an event was 9.2 months (8.1-10.7) in the 90 mg group and 10-2 months (7.3-14.0) in the 30 mg group (p=0.63). In a retrospective analysis, eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group. Interpretation Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Carlson, KristinaUppsala universitet,Medicin,Hematologi(Swepub:uu)krica965 (författare)
  • Turesson, IngemarLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)medf-itu (författare)
  • Fayers, PeterUniversity Aberdeen (författare)
  • Waage, AndersSt Olavs University Hospital (författare)
  • Vangsted, AnnetteHerlev University Hospital (författare)
  • Mylin, AnneRigshosp, Copenhagen (författare)
  • Gluud, ChristianRigshosp, Copenhagen (författare)
  • Juliusson, GunnarÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US(Swepub:liu)gunju78 (författare)
  • Gregersen, HenrikUniversity Hospital Aalborg (författare)
  • Hjorth-Hansen, HenrikSt Olavs University Hospital (författare)
  • Nesthus, IngeridHaukeland Hospital (författare)
  • Marie S Dahl, IngerUniversity Tromso Hospital (författare)
  • Westin, JanSahlgrens University Hospital (författare)
  • Lanng Nielsen, JohanArhus University Hospital (författare)
  • Meldgaard Knudsen, LeneHerlev University Hospital (författare)
  • Ahlberg, LuciaÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US(Swepub:liu)lucah64 (författare)
  • Hjorth, MartinLidkoping Hospital (författare)
  • Abildgaard, NielsOdense University Hospital (författare)
  • Frost Andersen, NielsArhus University Hospital (författare)
  • Linder, OlleOrebro University Hospital (författare)
  • Wisloeff, FinnUllevaal University Hospital (författare)
  • Rigshosp, CopenhagenMedicin (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:LANCET ONCOLOGY: Elsevier Science B.V., Amsterdam.11:10, s. 973-9821470-20451474-5488

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy